• If you are wondering whether Celcuity at US$139.44 still offers value after its run, the key question is how its fundamentals stack up against that price.
• The stock has moved sharply in recent periods, with returns of 17.2% over 7 days, 22.1% over 30 days, 38.7% year to date, and a very large 1 year gain accompanied by a 3 year return of 13x and a 5 year return of 4x.
• These moves sit against a backdrop of ongoing interest in Celcuity's role in the pharmaceuticals and biotech space. In this area, investors often focus closely on pipelines, trial progress, and funding runway. Recent attention around the stock has largely centred on these factors and how they might affect future prospects and risk.
• Simply Wall St currently gives Celcuity a valuation score of 2 out of 6, which means it screens as undervalued on 2 of 6 checks. The next sections will walk through the standard valuation tools used to get there before finishing with a broader way to think about what that score really means for you.

Celcuity scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Celcuity Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s value to estimate what the stock could be worth right now.

For Celcuity, the latest twelve month Free Cash Flow is a loss of about $153.5 million. Analysts provide Free Cash Flow estimates out to 2030, and Simply Wall St then extrapolates further to build a 2 Stage Free Cash Flow to Equity model. On this basis, projected Free Cash Flow for 2030 is about $815.5 million, with additional estimated figures for 2031 to 2035 included in the model to capture the longer term profile.

When all those future cash flows are discounted back to today using this approach, the model produces an estimated intrinsic value of about $762.68 per share. Compared with the current share price of US$139.44, this implies the stock screens as 81.7% undervalued under these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Celcuity is undervalued by 81.7%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Celcuity Price vs Book

For profitable companies, price based multiples are often a quick way to check whether the market price lines up with fundamentals. P/B is most useful for asset focused businesses or when earnings are not yet a stable guide, because it compares what you pay for each dollar of accounting equity.

In general, higher growth expectations and lower perceived risk can justify a higher multiple, while slower growth or higher risk usually points to a lower, more conservative range. That is why simply quoting a single “normal” P/B or P/E in isolation can be misleading.

Celcuity currently trades on a P/B of 67.03x. This sits well above the Biotechs industry average P/B of 2.46x and the peer group average of 10.79x. To refine that comparison, Simply Wall St uses a proprietary “Fair Ratio,” which estimates what a reasonable P/B might be after considering earnings growth, profit margins, industry, market cap and specific risk factors. This Fair Ratio is designed to be more tailored than a broad industry or peer comparison because it adjusts for the company’s own profile.

Simply Wall St does not currently publish a Fair Ratio figure for Celcuity, so a P/B based conclusion on mispricing cannot be drawn here.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Celcuity Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St take that further by letting you attach a clear story for Celcuity to the numbers you care about. This links your view on its pipeline, margins and funding to a specific forecast and Fair Value, then compares that to today’s price to help you decide whether you see the stock as ahead of itself or offering room for upside.

Within the Community page, you can choose or build a Narrative that fits how you see Celcuity. For example, one user might lean toward the higher Fair Value of US$165.00 based on assumptions around US$1.3b of revenue and US$458.9m of earnings by 2029. Another might anchor to the lower Fair Value of US$94.00 using revenue of US$414.4m and earnings of US$129.7m. The platform keeps updating these stories as new earnings, trial results or regulatory news arrive so your Fair Value view stays aligned with fresh information rather than a static one off model.

For Celcuity however, we will make it really easy for you with previews of two leading Celcuity Narratives:

Think of these as two different ways investors are joining the dots between the company’s pipeline, funding and today’s share price. You can then decide which set of assumptions feels closer to your own view.

Fair Value: US$165.00

Implied discount to this Fair Value at US$139.44: about 15%.

Forecast revenue growth used in this view: 979.25%.

• Assumes gedatolisib converts priority FDA review and VIKTORIA 1 data into a sizeable commercial opportunity, with potential peak annual sales of up to US$2.5b in second line disease alone.
• Builds in bullish analyst forecasts, with revenue of US$1.3b and earnings of US$458.9m by 2029, supported by a 36.5% profit margin and a P/E of 26.3x on those earnings.
• Accepts execution and funding risks, but takes the view that the current commercial build out and cash of US$441.5m through 2027 are sufficient to reach a more profitable phase.

Fair Value: US$94.00

Implied premium to this Fair Value at US$139.44: about 48%.

Forecast revenue growth used in this view: 645.54%.

• Focuses on concentration in a single drug, heavy use of external financing and the need for large, long duration trials across multiple tumor types before cash flows have a chance to catch up.
• Uses more cautious analyst assumptions, with 2029 revenue of US$414.4m, earnings of US$129.7m and a 31.3% margin, which still require a high 50.6x P/E on those earnings to justify the Fair Value.
• Highlights the risk that commercial build out, interest costs and potential dilution could weigh on future net margins and earnings if physician adoption, reimbursement or international partnerships are slower than expected.

If you want to see each storyline in full, including the detailed catalysts, risks and valuation logic that sit behind these numbers, you can step through the complete narratives, compare them side by side and check which assumptions line up with your own view of Celcuity.

Do you think there's more to the story for Celcuity? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.